These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15342613)

  • 1. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
    Agrawal NG; Matthews CZ; Mazenko RS; Woolf EJ; Porras AG; Chen X; Miller JL; Michiels N; Wehling M; Schultz A; Gottlieb AB; Kraft WK; Greenberg HE; Waldman SA; Curtis SP; Gottesdiener KM
    J Clin Pharmacol; 2004 Oct; 44(10):1125-31. PubMed ID: 15342613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.
    Hynninen VV; Olkkola KT; Neuvonen PJ; Laine K
    Eur J Clin Pharmacol; 2009 Jan; 65(1):89-95. PubMed ID: 18777173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
    Agrawal NG; Porras AG; Matthews CZ; Woolf EJ; Miller JL; Mukhopadhyay S; Neu DC; Gottesdiener KM
    J Clin Pharmacol; 2001 Oct; 41(10):1106-10. PubMed ID: 11583479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
    Agrawal NG; Porras AG; Matthews CZ; Rose MJ; Woolf EJ; Musser BJ; Dynder AL; Mazina KE; Lasseter KC; Hunt TL; Schwartz JI; McCrea JB; Gottesdiener KM
    J Clin Pharmacol; 2003 Mar; 43(3):268-76. PubMed ID: 12638395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.
    Schwartz JI; Agrawal NG; Wehling M; Musser BJ; Gumbs CP; Michiels N; De Smet M; Wagner JA
    Br J Clin Pharmacol; 2008 Dec; 66(6):811-7. PubMed ID: 18823299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
    Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
    J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.
    Kassahun K; McIntosh IS; Shou M; Walsh DJ; Rodeheffer C; Slaughter DE; Geer LA; Halpin RA; Agrawal N; Rodrigues AD
    Drug Metab Dispos; 2001 Jun; 29(6):813-20. PubMed ID: 11353749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of etoricoxib in patients with hepatic impairment.
    Agrawal NG; Rose MJ; Matthews CZ; Woolf EJ; Porras AG; Geer LA; Larson PJ; Cote J; Dilzer SC; Lasseter KC; Alam I; Petty KJ; Gottesdiener KM
    J Clin Pharmacol; 2003 Oct; 43(10):1136-48. PubMed ID: 14517196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
    Dallob A; Hawkey CJ; Greenberg H; Wight N; De Schepper P; Waldman S; Wong P; DeTora L; Gertz B; Agrawal N; Wagner J; Gottesdiener K
    J Clin Pharmacol; 2003 Jun; 43(6):573-85. PubMed ID: 12817520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
    Lathia C; Lettieri J; Cihon F; Gallentine M; Radtke M; Sundaresan P
    Cancer Chemother Pharmacol; 2006 May; 57(5):685-92. PubMed ID: 16133532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.
    Schwartz J; Hunt T; Smith WB; Wong P; Larson P; Crumley T; Mehta A; Gottesdiener K; Agrawal N
    J Clin Pharmacol; 2009 Jul; 49(7):807-15. PubMed ID: 19443681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.
    Mahatthanatrakul W; Nontaput T; Ridtitid W; Wongnawa M; Sunbhanich M
    J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
    Stroh M; Palcza J; McCrea J; Marsilio S; Breidinger S; Panebianco D; Johnson-Levonas A; Kraft WK; Orford K; Murphy G; Agrawal N; Trucksis M; Wagner JA; Iwamoto M
    Cancer Chemother Pharmacol; 2012 May; 69(5):1247-53. PubMed ID: 22290273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.
    Takemoto JK; Reynolds JK; Remsberg CM; Vega-Villa KR; Davies NM
    Clin Pharmacokinet; 2008; 47(11):703-20. PubMed ID: 18840026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration.
    Seidegård J
    Clin Pharmacol Ther; 2000 Jul; 68(1):13-7. PubMed ID: 10945311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
    Rodrigues AD; Halpin RA; Geer LA; Cui D; Woolf EJ; Matthews CZ; Gottesdiener KM; Larson PJ; Lasseter KC; Agrawal NG
    Drug Metab Dispos; 2003 Feb; 31(2):224-32. PubMed ID: 12527704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
    Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
    J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.